Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals (MIRM) delivers innovative therapies for rare liver diseases through targeted IBAT inhibitor development. This page provides centralized access to official announcements, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and healthcare professionals will find timely updates on regulatory milestones, partnership agreements, and pipeline advancements. Our curated feed includes verified press releases about Maralixibat approvals, Volixibat trial progress, and corporate initiatives addressing conditions like progressive familial intrahepatic cholestasis.
Key updates cover FDA communications, research collaborations, and commercialization strategies for orphan drug therapies. All content is sourced directly from Mirum’s disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Mirum’s latest advancements in minimally absorbed liver disease treatments. Check regularly for critical updates impacting clinical development timelines and therapeutic availability.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced first patient enrollment in the BLOOM Phase 2 study of oral MRM-3379 for Fragile X syndrome (FXS).
The randomized trial will evaluate safety, tolerability, and potential clinical benefit in males with a confirmed FMR1 mutation. Top-line data are expected in 2027. The company noted preclinical cognitive and behavioral improvements and favorable tolerability in healthy volunteers. Interested participants can find the study under NCT07209462 on clinicaltrials.gov.
Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in two investor conferences the week of December 2, 2025: the 8th Annual Evercore HealthCONx Conference with a company presentation on Tuesday, December 2 at 2:10 p.m. ET, and Citi’s 2025 Global Healthcare Conference on Wednesday, December 3. Investors can access webcast links and additional information via the company’s Investors and Media webpage.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced on November 10, 2025 that its Compensation Committee granted inducement awards to 11 new employees under the 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards consist of 53,500 non-qualified stock options and 27,950 restricted stock units (RSUs). Each option has an exercise price of $69.71, equal to Mirum’s closing price on November 10, 2025. Options vest over four years with 25% vesting at the first anniversary and the remainder vesting monthly over 36 months; RSUs vest over three years with 33% vesting on each anniversary, in each case subject to continued service and the terms of the 2020 Inducement Plan and applicable award agreements.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced multiple presentations at AASLD’s The Liver Meeting®, November 7-11, 2025, in Washington, D.C., highlighting new clinical and real-world data for LIVMARLI (maralixibat) and volixibat.
Key items include an oral presentation on additional VANTAGE trial analyses showing volixibat improvements in fatigue and sleep for adults with primary biliary cholangitis (PBC) on November 10, multiple poster presentations on maralixibat real-world pruritus reduction, genetic testing insights from 856 panel tests, IL-31 and bile acid regulation data, and a Mirum-sponsored PFIC diagnosis and treatment fireside discussion on November 9.
Full abstracts are available on the AASLD website and detailed analyses will be posted on Mirum’s publications page after the conference.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported Q3 2025 total revenue of $133.0 million and updated 2025 revenue guidance to $500–$510 million. Q3 LIVMARLI net sales were $92.2 million (+56% vs Q3 2024); Bile Acid Medicines sales were $40.8 million (+31% vs Q3 2024). Total operating expenses were $130.4 million in Q3 2025, including $24.0 million of non-cash stock-based compensation and amortization. Cash, cash equivalents, and investments were $378.0 million as of September 30, 2025.
Pipeline catalysts: VISTAS (volixibat) enrollment complete with topline data expected in Q2 2026; VANTAGE and EXPAND expected to read out in H1 2027; Phase 2 MRM-3379 in Fragile X initiated. Company hosted a conference call on November 4, 2025.
Mirum Pharmaceuticals (Nasdaq: MIRM) said it will participate in two investor events in November 2025: a company presentation at the 2025 Stifel Healthcare Conference on Tuesday, November 11 at 8:40 a.m. ET and attendance at the J.P. Morgan U.S. Opportunities Forum 2025 on Wednesday, November 12.
Investors can find webcast links and additional information in the Investors and Media section of Mirum’s corporate website.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report third quarter 2025 financial results on November 4, 2025 and host a conference call the same day to discuss results and recent corporate progress.
The call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT on Tuesday, November 4, 2025. Dial-in numbers: US toll-free +1 833 470 1428; International +1 646 844 6383; Access Code: 299722. A live webcast will be available in the Events & Presentations section on Mirum’s website and a replay will be available for 30 days.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement equity awards on October 10, 2025 to eight new employees under its 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee granted non‑qualified stock options to purchase 45,800 shares with an exercise price of $72.71 (Mirum's closing price on October 10, 2025) and 22,850 restricted stock units (RSUs). Options vest over four years (25% at one year, then monthly over 36 months); RSUs vest over three years (33% each anniversary), each subject to continued service and the applicable award agreements.
Mirum Pharmaceuticals (NASDAQ:MIRM) announced the granting of inducement awards to four new employees under its 2020 Inducement Plan. The awards, approved by the Compensation Committee, include non-qualified stock options to purchase 10,820 shares at $74.89 per share and 5,390 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually, subject to continued employment.
Mirum Pharmaceuticals (Nasdaq: MIRM) has completed enrollment in its Phase 2b VISTAS study evaluating volixibat, an oral IBAT inhibitor, for treating cholestatic pruritus in primary sclerosing cholangitis (PSC) patients. The trial previously met its pre-specified efficacy and safety thresholds during a blinded interim analysis in 2024.
Topline results from the VISTAS study are expected in Q2 2026. Additionally, volixibat is being evaluated in the Phase 2b VANTAGE study for primary biliary cholangitis (PBC), with enrollment completion expected in 2026 and topline results in H1 2027.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
